 The French authority has signed off XBiotech Incs NASDAQ: XBIT multicenter randomized clinical study for Natrunix combined with trifluridinetipiracil for colorectal cancer. The French National Cancer Institute INCA has also awarded a grant to fund all clinical costs. 